Eisai expects 13x jump in Leqembi revenue for FY25 to ¥56.5B, driven by progress in AD treatment pathways in U.S. and Japan, and China launch. A competitor drug is likely to get FDA approval in 3Q24.
What is covered in the Full Insight:
Eisai Co Ltd's Leqembi Revenue Guidance
Leqembi's Growth Prospects
Competitive Landscape
Leqembi's Potential Market in China
Eisai's Future Outlook
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.